| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Review |

From the International Agency for Research on Cancer,* Lyon, France; and the Department of Pathology,
University of Zurich, Zurich, Switzerland
Abstract
Glioblastoma is the most frequent and most malignant human brain tumor. The prognosis remains very poor, with most patients dying within 1 year after diagnosis. Primary and secondary glioblastoma constitute distinct disease subtypes, affecting patients of different age and developing through different genetic pathways. The majority of cases (>90%) are primary glioblastomas that develop rapidly de novo, without clinical or histological evidence of a less malignant precursor lesion. They affect mainly the elderly and are genetically characterized by loss of heterozygosity 10q (70% of cases), EGFR amplification (36%), p16INK4a deletion (31%), and PTEN mutations (25%). Secondary glioblastomas develop through progression from low-grade diffuse astrocytoma or anaplastic astrocytoma and manifest in younger patients. In the pathway to secondary glioblastoma, TP53 mutations are the most frequent and earliest detectable genetic alteration, already present in 60% of precursor low-grade astrocytomas. The mutation pattern is characterized by frequent G:C
A:T mutations at CpG sites. During progression to glioblastoma, additional mutations accumulate, including loss of heterozygosity 10q25-qter (
70%), which is the most frequent genetic alteration in both primary and secondary glioblastomas. Primary and secondary glioblastomas also differ significantly in their pattern of promoter methylation and in expression profiles at RNA and protein levels. This has significant implications, particularly for the development of novel, targeted therapies, as discussed in this review.
This article has been cited by other articles:
![]() |
B. Neyns, J. Sadones, E. Joosens, F. Bouttens, L. Verbeke, J.-F. Baurain, L. D'Hondt, T. Strauven, C. Chaskis, P. In't Veld, et al. Stratified phase II trial of cetuximab in patients with recurrent high-grade glioma Ann. Onc., June 2, 2009; (2009) mdp032v1. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Watanabe, S. Nobusawa, P. Kleihues, and H. Ohgaki IDH1 Mutations Are Early Events in the Development of Astrocytomas and Oligodendrogliomas Am. J. Pathol., April 1, 2009; 174(4): 1149 - 1153. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Zhu, A. Wloch, Q. Wu, C. Peters, A. Pagenstecher, H. Bertalanffy, and U. Sure Involvement of PTEN Promoter Methylation in Cerebral Cavernous Malformations Stroke, March 1, 2009; 40(3): 820 - 826. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Yan, D. W. Parsons, G. Jin, R. McLendon, B. A. Rasheed, W. Yuan, I. Kos, I. Batinic-Haberle, S. Jones, G. J. Riggins, et al. IDH1 and IDH2 Mutations in Gliomas N. Engl. J. Med., February 19, 2009; 360(8): 765 - 773. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. Suri, P. Das, A. Jain, M. C. Sharma, S. A. Borkar, A. Suri, D. Gupta, and C. Sarkar Pediatric glioblastomas: A histopathological and molecular genetic study Neuro-oncol, January 1, 2009; 11(3): 274 - 280. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. B. Dinca, K. V. Lu, J. N. Sarkaria, R. O. Pieper, M. D. Prados, D. A. Haas-Kogan, S. R. VandenBerg, M. S. Berger, and C. D. James p53 Small-Molecule Inhibitor Enhances Temozolomide Cytotoxic Activity against Intracranial Glioblastoma Xenografts Cancer Res., December 15, 2008; 68(24): 10034 - 10039. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. C. Milsom, J. L. Yu, N. Mackman, J. Micallef, G. M. Anderson, A. Guha, and J. W. Rak Tissue Factor Regulation by Epidermal Growth Factor Receptor and Epithelial-to-Mesenchymal Transitions: Effect on Tumor Initiation and Angiogenesis Cancer Res., December 15, 2008; 68(24): 10068 - 10076. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. H. Garfield and A. Hercbergs Fewer Dollars, More Sense J. Clin. Oncol., November 10, 2008; 26(32): 5304 - 5305. [Full Text] [PDF] |
||||
![]() |
T. Kato, J. Shinoda, N. Oka, K. Miwa, N. Nakayama, H. Yano, T. Maruyama, Y. Muragaki, and T. Iwama Analysis of 11C-methionine Uptake in Low-Grade Gliomas and Correlation with Proliferative Activity AJNR Am. J. Neuroradiol., November 1, 2008; 29(10): 1867 - 1871. [Abstract] [Full Text] [PDF] |
||||
![]() |
J.-H. Walzlein, M. Synowitz, B. Engels, D. S. Markovic, K. Gabrusiewicz, E. Nikolaev, K. Yoshikawa, B. Kaminska, G. Kempermann, W. Uckert, et al. The Antitumorigenic Response of Neural Precursors Depends on Subventricular Proliferation and Age Stem Cells, November 1, 2008; 26(11): 2945 - 2954. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. J. Attenello, D. Mukherjee, G. Datoo, M. J. McGirt, E. Bohan, J. D. Weingart, A. Olivi, A. Quinones-Hinojosa, and H. Brem Use of Gliadel (BCNU) Wafer in the Surgical Treatment of Malignant Glioma: A 10-Year Institutional Experience Ann. Surg. Oncol., October 1, 2008; 15(10): 2887 - 2893. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. W Buie and J. Valgus Bevacizumab: A Treatment Option for Recurrent Glioblastoma Multiforme Ann. Pharmacother., October 1, 2008; 42(10): 1486 - 1490. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. W. Parsons, S. Jones, X. Zhang, J. C.-H. Lin, R. J. Leary, P. Angenendt, P. Mankoo, H. Carter, I-M. Siu, G. L. Gallia, et al. An Integrated Genomic Analysis of Human Glioblastoma Multiforme Science, September 26, 2008; 321(5897): 1807 - 1812. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Y. Wen and S. Kesari Malignant Gliomas in Adults N. Engl. J. Med., July 31, 2008; 359(5): 492 - 507. [Full Text] [PDF] |
||||
![]() |
W. P. Mason and J. G. Cairncross Invited Article: The expanding impact of molecular biology on the diagnosis and treatment of gliomas Neurology, July 29, 2008; 71(5): 365 - 373. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. G. Davis, B. S. Malmer, K. Aldape, J. S. Barnholtz-Sloan, M. L. Bondy, T. Brannstrom, J. M. Bruner, P. C. Burger, V. P. Collins, P. D. Inskip, et al. Issues of Diagnostic Review in Brain Tumor Studies: From the Brain Tumor Epidemiology Consortium Cancer Epidemiol. Biomarkers Prev., March 1, 2008; 17(3): 484 - 489. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. Yang, G. Wu, R. F. Barth, M. R. Swindall, A. K. Bandyopadhyaya, W. Tjarks, K. Tordoff, M. Moeschberger, T. J. Sferra, P. J. Binns, et al. Molecular Targeting and Treatment of Composite EGFR and EGFRvIII-Positive Gliomas Using Boronated Monoclonal Antibodies Clin. Cancer Res., February 1, 2008; 14(3): 883 - 891. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. C. Short, C. Martindale, S. Bourne, G. Brand, M. Woodcock, and P. Johnston DNA repair after irradiation in glioma cells and normal human astrocytes Neuro-oncol, October 1, 2007; 9(4): 404 - 411. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |